About Allogene Therapeutics, Inc
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California. Address: 210 East Grand Avenue, South San Francisco, CA, United States, 94080
Allogene Therapeutics, Inc News and around…
Latest news about Allogene Therapeutics, Inc (ALLO) common stock and company :
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Over the past 3 months, 5 analysts have published their opinion on Allogene Therapeutics (NASDAQ:ALLO) stock. These analysts ...
Allogene's (ALLO) second-quarter earnings beat estimates. ALLO is on track to initiate a pivotal phase II study on ALLO-501A in large B cell lymphoma in the coming weeks.
Upgrades According to Stifel, the prior rating for V2X Inc (NYSE:VVX) was changed from Hold to Buy. The current stock ...
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 14.75% and 7.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Allogene Therapeutics (NASDAQ:ALLO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's ...
U.S. FDA Clearance on Potential Pivotal Phase 2 Trial of ALLO-501A Anticipated in Coming Weeks Expected to be the Industry’s First Allogeneic CAR T Phase 2 Pivotal TrialClearance to Cover ALPHA2 Protocol and Chemistry Manufacturing and Controls (CMC) for Use of ALLO-501A Manufactured from Cell Forge 1 (CF1)CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale CF1 Earned a LEED® Interior Design and Construction Gold Designation from the U.S Green Bu
A Relative Strength Rating upgrade for Allogene Thera shows improving technical performance.
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that management plans to participate in three upcoming investor conferences. 42nd Annual Canaccord Genuity Growth ConferenceThursday, August 11, 2022Noon PT/3:00PM ET H.C. Wainwright 24th Annual Global Investment ConferenceMonday, September 12, 2022Presenta
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the ProShares Ultra Health Care ETF (RXL), we found that the implied analyst target price for the ETF based upon its underlying holdings is $103.49 per unit.
A clinical hold is weighing on the biotech's shares today.
Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ETSOUTH SAN FRANCISCO, Calif., July 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will report second quarter 2022 financial results on Tuesday, August 9, 2022, after the close of the market. The announcement will be followed by a live audio webcast and conference call
According to its website, Allogene Therapeutics is developing allogeneic chimeric antigen receptor T cell products to find the next immunologic breakthrough in cancer -- cutting edge stuff and way above my pay grade.
Markets turned down in the first six months of this year, but they’ve trended up in July. Despite Friday’s pullback, the monthly gains are solid, almost 5% on the S&P 500 and 7.5% on the NASDAQ, marking a turnaround from the long drop we saw earlier. The question investors have is, is this turnaround real, or just a temporary gain in a larger bearish trend. That remains to be seen, but either way, even if the market reverts to its bearish trend, there will be opportunities for investors - findin
One of the most powerful tradable market events is a short squeeze, so traders are always on the lookout for the next short squeeze ...
Investors in Allogene Therapeutics Inc (ALLO) saw new options begin trading this week, for the September 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ALLO options chain for the new September 16th contracts and identified one put and one call contract of particular interest.
In trading on Friday, shares of Allogene Therapeutics Inc (ALLO) crossed above their 200 day moving average of $12.54, changing hands as high as $14.06 per share. Allogene Therapeutics Inc shares are currently trading up about 4% on the day..
Upgrades B of A Securities upgraded the previous rating for TechnipFMC PLC (NYSE:FTI) from Neutral to Buy. For the first ...
Gainers NexImmune (NASDAQ:NEXI) shares moved upwards by 29.9% to $1.91 during Friday's pre-market session. The ...
SOUTH SAN FRANCISCO, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert in computational protein design, to the company’s Board of Directors. “We are privileged to have Dr. Mayo join our Board of Directors,” said David Chang, M.D., Ph.D., President, CEO and Co-F
Gainers Revlon, Inc. (NYSE: REV) jumped 91.3% to close at $3.73 on Friday after the company filed for Chapter 11 ...
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Allogene Therapeutics (ALLO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
RMAT Designation Follows Positive Data from ALLO-501A ALPHA2 Trial in Heavily Pretreated Patients with Relapsed or Refractory Large B cell Lymphoma (LBCL) Data Presented at the American Society of Hematology (ASH) 2021 Annual Meeting Demonstrated AlloCAR T™ Could be Safe and Effective in Producing Durable ResponsesIn the ALPHA Trials with ALLO-501 and ALLO-501A, Treatment was Initiated Approximately 2 Days from Enrollment, Eliminating Any Need for Bridging Therapy Company Intends to Initiate a P
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Upgrades Keefe, Bruyette & Woods upgraded the previous rating for Regions Financial Corp (NYSE:RF) from Underperform ...
Analysts have provided the following ratings for Allogene Therapeutics (NASDAQ:ALLO) within the last quarter: ...
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones US.
Cells Derived from Healthy, Younger Donors were More Abundant with Greater Fitness and Cancer Killing Potential Than Cells Derived from Patients with CancerFindings Underscore Potential of Allogeneic CAR T Products to Improve Patient Outcomes SOUTH SAN FRANCISCO, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today will present preclinical
Gainers Allogene Therapeutics (NASDAQ:ALLO) shares increased by 12.7% to $7.98 during Tuesday's pre-market session. ...
Allogene Therapeutics, Inc (ALLO) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
